论文部分内容阅读
目的:探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)生物免疫治疗联合放疗及中药在肝癌治疗过程中的应用效果。方法:将2012年2月至2015年5月间于本院接受治疗的80例肝癌患者作为观察对象,并以随机数字表法将患者随机分为对照组和观察组,每组40例。以接受放疗治疗者为对照组,接受DC-CIK联合放疗及中药治疗者为观察组。在患者接受8周治疗后对两组治疗前后的免疫指标变化情况及肿瘤治疗效果进行评价。结果:入组接受治疗前两组间CD_3~+、CD_3~+CD_4~+、CD_3~+CD_8~+、NK及AFP比较未见统计学差异(P>0.05),而在接受治疗8周后,观察组CD_3~+、CD_3~+CD_4~+、CD_3~+CD_8~+及NK明显高于对照组,AFP低于对照组(P<0.05)。同时在接受治疗8周后,观察组治疗总有效率明显高于对照组(P<0.05)。在接受治疗8周后,与对照组对比,观察组患者不良反应发生率显著降低(P<0.05)。结论:DC-CIK生物免疫治疗联合放疗及中药治疗肝癌,可有效地改善肝癌患者的免疫细胞,并提高患者的临床治疗效果。
Objective: To investigate the effect of dendritic cell-cytokine-induced killer (DC-CIK) bioimmunotherapy combined with radiotherapy and traditional Chinese medicine in the treatment of liver cancer. Methods: 80 patients with HCC treated in our hospital from February 2012 to May 2015 were selected as the observation subjects. Patients were randomly divided into control group and observation group with random number table method, 40 cases in each group. To accept radiotherapy as control group, receiving DC-CIK combined with radiotherapy and Chinese medicine treatment for the observation group. The patients received eight weeks of treatment before and after treatment on the changes in immune indicators and treatment of cancer were evaluated. Results: There was no significant difference in the levels of CD_3 ~ +, CD_3 ~ + CD_4 ~ +, CD_3 ~ + CD_8 ~ +, NK and AFP between the two groups before treatment (P> 0.05) (P <0.05). The levels of CD_3 ~ +, CD_3 ~ + CD_4 ~ +, CD_3 ~ + CD_8 ~ + and NK in the observation group were significantly higher than those in the control group. At the same time, after treatment for 8 weeks, the total effective rate of observation group was significantly higher than that of control group (P <0.05). After 8 weeks of treatment, compared with the control group, the incidence of adverse reactions in the observation group was significantly decreased (P <0.05). Conclusion: DC-CIK bioimmunotherapy combined with radiotherapy and traditional Chinese medicine in the treatment of hepatocellular carcinoma can effectively improve the immune cells of patients with hepatocellular carcinoma and improve the clinical therapeutic effect.